"We saw continued stability in our MS business, executed a strong launch of Spinraza, grew market share for our biosimilars business across Europe, and reinforced the intellectual property for Tecfidera," Chief Executive Officer Michel Vounatsos said in a statement.

Spinraza is the first major drug launch under Vounatsos, who succeeded George Scangos in January.

Sales of Biogen's multiple sclerosis (MS) drug Tysabri came in at $545 million, also well ahead of the consensus estimate of $484 million.

Sales in the latest quarter were boosted by $45 million from an agreement with the Italian health regulator related to prior Tysabri sales.